市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Palisade Bio, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.42 |
|
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.46% |
| 机构持股比例 | 5.43% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Soleus Capital Management, L.P. | 30 Jun 2026 | 13,063,687 |
| Ameriprise Financial Inc | 30 Jun 2026 | 11,081,434 |
| Janus Henderson Group Ltd. | 31 Mar 2026 | 10,689,452 |
| Jupiter Topco Llc | 30 Jun 2026 | 10,689,452 |
| Octagon Capital Advisors Lp | 30 Jun 2026 | 10,276,317 |
| Perceptive Advisors Llc | 30 Jun 2026 | 8,425,065 |
| Ra Capital Management, L.P. | 30 Jun 2026 | 7,124,116 |
| Franklin Templeton Inc | 30 Jun 2026 | 5,785,189 |
| Point72 Asset Management, L.P. | 30 Jun 2026 | 5,253,403 |
| Boxer Capital Management, Llc | 30 Jun 2026 | 4,799,875 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2026 | 4,500,000 |
| Eversept Partners, Lp | 30 Jun 2026 | 4,182,785 |
该时间范围内无数据。
投资组合